Stockscreener 앱 받기
3.7606
1.04%
-0.0394
전일 마감가:
$3.80
열려 있는:
$3.7724
하루 거래량:
1,098
Relative Volume:
0.08
시가총액:
$68.78M
수익:
-
순이익/손실:
$-12.63M
주가수익비율:
-5.4172
EPS:
-0.6942
순현금흐름:
$-12.18M
1주 성능:
+7.14%
1개월 성능:
+1.59%
6개월 성능:
-5.75%
1년 성능:
-6.92%
1일 변동 폭
$3.7606
$3.7724
1주일 범위
$3.3298
$4.50
52주 변동 폭
$2.74
$7.28
Genenta Science Spa Adr Stock (GNTA) Company Profile
GNTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GNTA
Genenta Science Spa Adr
|
3.7606 | 69.50M | 0 | -12.63M | -12.18M | -0.6942 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-06-29 | 재개 | ROTH MKM | Buy |
| 2022-07-25 | 개시 | H.C. Wainwright | Buy |
| 2022-01-13 | 개시 | Maxim Group | Buy |
Genenta Science Spa Adr 주식(GNTA)의 최신 뉴스
Real time alert setup for Trinity Capital Inc. performanceJuly 2025 Drop Watch & Capital Protection Trading Alerts - Newser
Using data filters to optimize entry into Genenta Science S.p.A. Depositary ReceiptJuly 2025 News Drivers & High Accuracy Investment Signals - Newser
Assembly Biosciences Inc. stock trend outlook and recovery pathGDP Growth & Safe Capital Growth Tips - Newser
Genenta Science S.p.A. to Terminate Dedicated Suite Agreement with AGC Biologics - MSN
Will Genenta Science S.p.A. Depositary Receipt stock go up soonJuly 2025 News Drivers & Entry and Exit Point Strategies - Newser
How moving averages guide Genenta Science S.p.A. Depositary Receipt tradingTrade Signal Summary & Safe Capital Investment Plans - Newser
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
Applying sector rotation models to Altice USA Inc.Free Risk Managed Intraday Trade Alerts - Newser
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
Genenta Science stock maintains Buy rating as Temferon shows promise in GBM - Investing.com
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar - GlobeNewswire Inc.
Genenta secures $21.9 million for cancer drug trial By Investing.com - Investing.com South Africa
Genenta secures €20M in mandatory convertible bond deal - Investing.com India
Genenta secures €20M in mandatory convertible bond deal By Investing.com - Investing.com South Africa
Genenta secures $21.9 million for cancer drug trial - Investing.com India
Genenta Science Secures €20 Million Convertible Bond Financing for Oncology Research - TipRanks
Oncology Breakthroughs: How Cancer Research Is Advancing in 202527.02.25News - Ariva
Genenta Science announces amendment to pact with AGC Biologics - Yahoo Finance
Genenta Science Enhances Manufacturing Agreement with AGC Biologics - TipRanks
Genenta Science Announces Shareholder Meeting - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
10 Best Italian Stocks To Buy Now - Yahoo Finance
Trading Halts Explained - MarketBeat
Genenta Science Spa Adr (GNTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.96%
1.09%
자본화:
|
볼륨(24시간):